Novo Nordisk (NVO) Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access

Simply Wall St.06:33

Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy. The U.S. Medicare program began covering the company’s GLP-1 injections for eligible patients. Novo...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648937836?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-04 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648937836","market":"us","top_or_hot":-1,"title":"Novo Nordisk (NVO) Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access","media":"Simply Wall St.","content":"<div>\n<p>Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy. The U.S. Medicare program began covering the company’s GLP-1 injections for eligible patients. Novo...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-wins-uk-wegovy-pill-approval-as-medicare-op\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk (NVO) Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk (NVO) Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-04 06:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-wins-uk-wegovy-pill-approval-as-medicare-op><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy. The U.S. Medicare program began covering the company’s GLP-1 injections for eligible patients. Novo...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-wins-uk-wegovy-pill-approval-as-medicare-op\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-wins-uk-wegovy-pill-approval-as-medicare-op","article_id":"2648937836","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-wins-uk-wegovy-pill-approval-as-medicare-op","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648937836","pubTimestamp":1783117982,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy.\nThe U.S. Medicare program began covering the company’s GLP-1 injections for eligible patients.\nNovo Nordisk launched supplier cost-efficiency measures to respond to rising competition in GLP-1 treatments.\n\nNovo Nordisk (NYSE:NVO) is in focus after fresh approvals and reimbursement decisions related to its GLP-1 weight-loss treatments. The stock last closed at $50.43, with the share price up...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","NVOX":"2倍做多NVO ETF-Defiance","BK4599":"减肥药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","NVO":"诺和诺德","PPH":"VanEck Pharmaceutical ETF","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4532":"文艺复兴科技持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"随着Medicare开放GLP 1准入，诺和诺德(NVO)赢得英国Wegovy药丸批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.98,"OZEM":0.6,"PPH":0.6,"NVOX":0.6,"NVOH":0.6,"THNR":0.6},"content_text":"Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy. The U.S. Medicare program began covering the company’s GLP-1 injections for eligible patients. Novo Nordisk launched supplier cost-efficiency measures to respond to rising competition in GLP-1 treatments.  Novo Nordisk (NYSE:NVO) is in focus after fresh approvals and reimbursement decisions related to its GLP-1 weight-loss treatments. The stock last closed at $50.43, with the share price up 5.9% over the past week and 17.5% over the past month, while still down 3.7% year to date and 24.7% over the past year. These moves come as investors weigh expanding access to GLP-1 drugs alongside a tougher competitive backdrop. For investors, the combination of UK pill approval, new Medicare coverage and cost-efficiency efforts could influence expectations for how Novo Nordisk’s GLP-1 franchise is used and reimbursed. The company’s decision to tighten supplier costs indicates that management is preparing for a more crowded GLP-1 market, including competition from Eli Lilly. How effectively Novo Nordisk manages access and cost control is likely to be a key focus in upcoming quarters. Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk. NYSE:NVO Earnings & Revenue Growth as at Jul 2026 3 things going right for Novo Nordisk that this headline doesn't cover. AdvertisementQuick Assessment  ⚖️ Price vs Analyst Target: Novo Nordisk trades at US$50.43 versus a consensus target of US$47.95, around 5% above analysts’ central view. ✅ Simply Wall St Valuation: Simply Wall St estimates the stock is trading 48.1% below its calculated fair value, flagging a potential valuation gap. ✅ Recent Momentum: The share price is up 17.5% over the past 30 days, suggesting the market is reacting positively to the GLP-1 news flow.  There's only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St's company report for the latest analysis of Novo Nordisk's Fair Value. Key Considerations  📊 UK approval of the GLP-1 pill and new U.S. Medicare coverage for injections broaden the addressable patient pool for Novo Nordisk’s GLP-1 franchise. 📊 Watch how GLP-1 revenues, pricing trends and the impact of supplier cost-efficiency measures show up in future margins versus peers. ⚠️ Earnings are forecast to decline on average by 1% per year for the next 3 years, while the company also carries a high level of debt.  Dig Deeper For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can check out the community page for Novo Nordisk to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Novo Nordisk might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease,policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648937836","isCrawlerRequest":true}